Thymosin Alpha-1 vs. Thymalin: Choosing the Right Immune Modulator

Why the Thymus Matters for Longevity

The thymus — a bilobed lymphoid organ behind the sternum — reaches peak mass at puberty and involutes progressively thereafter, losing roughly 3% of functional tissue per year. By age 65, over 80% is adipose tissue. This thymic involution is a primary driver of immunosenescence: declining T-cell diversity, reduced vaccine response, increased cancer risk, and the systemic inflammatory state (inflammaging) that accelerates ageing.

Both Thymosin Alpha-1 and Thymalin attempt to restore what thymic involution takes away — but through different means.

Thymosin Alpha-1: The Characterised Peptide

Tα1 (28 amino acids, N-terminally acetylated) was isolated by Allan Goldstein's team in the 1970s and is now synthetically manufactured as the drug Zadaxin. It is approved in 40+ countries for: ^[]

• Hepatitis B adjuvant therapy
• Hepatitis C in combination with interferon
• Immunocompromised patients (chemotherapy, organ transplant)
• Malignant melanoma (as immune enhancer)

The mechanism is specific: Tα1 binds TLR-2 and TLR-9 on dendritic cells and T-cells, promoting T-cell maturation, Th1 polarisation, NK cell activation, and dendritic cell function. This is a characterised, defined pharmacological interaction.

COVID-19 data: A 2021 retrospective study of 76 severe COVID-19 patients found Tα1 treatment was associated with 28-day mortality of 11% versus 31% in controls — a striking signal that prompted widespread interest. While retrospective and non-randomised, the result is consistent with mechanistic predictions.

Thymalin: The Broad Extract

Thymalin is a polypeptide extract from bovine thymus — containing Tα1 and multiple other thymic peptides (Thymosin β-4, thymopoietin fragments, thymulin, and others). It is not a single characterised compound but a biological mixture.

The Khavinson Institute in St. Petersburg has conducted the most extensive thymalin research. Their landmark study enrolled 266 elderly patients (60–80 years) in a 15-year follow-up. ^[] Patients receiving annual thymalin + epithalon courses showed:

• 2-fold reduction in cardiovascular mortality vs. controls
• 44% reduction in respiratory disease mortality
• Improved immune function markers throughout the study

These are compelling numbers — but the study used a mixed intervention (thymalin + epithalon), used Soviet-era endpoints, and has limited Western replication.

Side-by-Side Comparison

| Feature | Thymosin Alpha-1 | Thymalin | |---|---|---| | Structure | Pure 28-aa peptide | Crude polypeptide extract | | Dose | 1.6mg SC | 10mg IM | | Evidence level | Phase 2/3 RCTs | Observational, Russian literature | | Approvals | 40+ countries | Russia, Eastern Europe | | Mechanism | Specific TLR2/9 agonism | Broad thymic peptide complex | | Best for | Specific immune modulation | Broader thymic rejuvenation |

When to Use Each

Thymosin Alpha-1 alone: Acute viral infection, post-chemotherapy immune restoration, vaccine enhancement, specific Th1/NK axis support.

Thymalin alone: Longevity protocols following Khavinson framework, general age-related immunosenescence, cost-conscious approach.

Combination: Advanced longevity protocols seeking both specific (Tα1) and broad (thymalin) thymic restoration. The Khavinson combination protocol is the evidence basis here.

Practical Protocol

Thymosin Alpha-1: 1.6mg SC, twice weekly (Monday/Thursday). 6–12 week cycles.

Thymalin: 10mg IM, once daily for 10 days. Repeat 2x/year.

Both can be combined by dosing in separate injection sites. Quarterly immune panel monitoring (T-cell subsets, NK activity, CD4/CD8 ratio) is ideal for tracking response.